Use of Bacteriophages in Lung Transplantation
Bacteriophages (phages) are natural predators of bacteria and are becoming increasingly attractive due to the increase of multidrug-resistant organisms (MDROs), especially prevalent among transplant recipients. Antibiotic resistance is the biggest current threat to global health. An increasing numbe...
Ausführliche Beschreibung
Autor*in: |
Manuel López-Meseguer [verfasserIn] Marta Zapata-Ortega [verfasserIn] Cristina Berastegui-Garcia [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2023 |
---|
Schlagwörter: |
Bacteriophages. Lung transplant. Multi-drug resistant organisms. |
---|
Übergeordnetes Werk: |
In: Barcelona Respiratory Network Reviews - Publicaciones Permanyer, 2022, 9(2023), 3 |
---|---|
Übergeordnetes Werk: |
volume:9 ; year:2023 ; number:3 |
Links: |
---|
DOI / URN: |
10.23866/BRNRev:2023-M0096 |
---|
Katalog-ID: |
DOAJ101681518 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ101681518 | ||
003 | DE-627 | ||
005 | 20240414203143.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240414s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.23866/BRNRev:2023-M0096 |2 doi | |
035 | |a (DE-627)DOAJ101681518 | ||
035 | |a (DE-599)DOAJec3039ef437e4deab69b8cb849b17568 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
050 | 0 | |a RC705-779 | |
100 | 0 | |a Manuel López-Meseguer |e verfasserin |4 aut | |
245 | 1 | 0 | |a Use of Bacteriophages in Lung Transplantation |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Bacteriophages (phages) are natural predators of bacteria and are becoming increasingly attractive due to the increase of multidrug-resistant organisms (MDROs), especially prevalent among transplant recipients. Antibiotic resistance is the biggest current threat to global health. An increasing number of infections is becoming harder or almost impossible to treat, carrying high morbidity, mortality and financial cost. The therapeutic use of bacteriophages, viruses that infect and kill bacteria, is well suited to be part of the strategies to combat antibiotic resistance. Infections, in particular those due to bacterial pathogens, are common among transplant candidates and recipients. For lung transplant (LTx) patients this is of paramount relevance, since some of the underlying diseases in LTx present recurrent infection and complex colonization (such as cystic fibrosis or bronchiectasis). Individual case reports and small case series suggest the possible efficacy of phage therapy for the treatment in pre- and posttransplant patients. Importantly, there have been no serious safety concerns in the reported cases, so it is reasonable to pursue phage therapy for difficult infections on a compassionate basis. | ||
650 | 4 | |a Bacteriophages. Lung transplant. Multi-drug resistant organisms. | |
653 | 0 | |a Diseases of the respiratory system | |
700 | 0 | |a Marta Zapata-Ortega |e verfasserin |4 aut | |
700 | 0 | |a Cristina Berastegui-Garcia |e verfasserin |4 aut | |
773 | 0 | 8 | |i In |t Barcelona Respiratory Network Reviews |d Publicaciones Permanyer, 2022 |g 9(2023), 3 |w (DE-627)1827079673 |x 23857110 |7 nnns |
773 | 1 | 8 | |g volume:9 |g year:2023 |g number:3 |
856 | 4 | 0 | |u https://doi.org/10.23866/BRNRev:2023-M0096 |z kostenfrei |
856 | 4 | 0 | |u https://doaj.org/article/ec3039ef437e4deab69b8cb849b17568 |z kostenfrei |
856 | 4 | 0 | |u https://www.brnreviews.com/frame_esp.php?id=237 |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/2462-3172 |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_DOAJ | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_31 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_206 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4367 | ||
912 | |a GBV_ILN_4700 | ||
951 | |a AR | ||
952 | |d 9 |j 2023 |e 3 |
author_variant |
m l m mlm m z o mzo c b g cbg |
---|---|
matchkey_str |
article:23857110:2023----::sobceipaeilntas |
hierarchy_sort_str |
2023 |
callnumber-subject-code |
RC |
publishDate |
2023 |
allfields |
10.23866/BRNRev:2023-M0096 doi (DE-627)DOAJ101681518 (DE-599)DOAJec3039ef437e4deab69b8cb849b17568 DE-627 ger DE-627 rakwb eng RC705-779 Manuel López-Meseguer verfasserin aut Use of Bacteriophages in Lung Transplantation 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Bacteriophages (phages) are natural predators of bacteria and are becoming increasingly attractive due to the increase of multidrug-resistant organisms (MDROs), especially prevalent among transplant recipients. Antibiotic resistance is the biggest current threat to global health. An increasing number of infections is becoming harder or almost impossible to treat, carrying high morbidity, mortality and financial cost. The therapeutic use of bacteriophages, viruses that infect and kill bacteria, is well suited to be part of the strategies to combat antibiotic resistance. Infections, in particular those due to bacterial pathogens, are common among transplant candidates and recipients. For lung transplant (LTx) patients this is of paramount relevance, since some of the underlying diseases in LTx present recurrent infection and complex colonization (such as cystic fibrosis or bronchiectasis). Individual case reports and small case series suggest the possible efficacy of phage therapy for the treatment in pre- and posttransplant patients. Importantly, there have been no serious safety concerns in the reported cases, so it is reasonable to pursue phage therapy for difficult infections on a compassionate basis. Bacteriophages. Lung transplant. Multi-drug resistant organisms. Diseases of the respiratory system Marta Zapata-Ortega verfasserin aut Cristina Berastegui-Garcia verfasserin aut In Barcelona Respiratory Network Reviews Publicaciones Permanyer, 2022 9(2023), 3 (DE-627)1827079673 23857110 nnns volume:9 year:2023 number:3 https://doi.org/10.23866/BRNRev:2023-M0096 kostenfrei https://doaj.org/article/ec3039ef437e4deab69b8cb849b17568 kostenfrei https://www.brnreviews.com/frame_esp.php?id=237 kostenfrei https://doaj.org/toc/2462-3172 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 9 2023 3 |
spelling |
10.23866/BRNRev:2023-M0096 doi (DE-627)DOAJ101681518 (DE-599)DOAJec3039ef437e4deab69b8cb849b17568 DE-627 ger DE-627 rakwb eng RC705-779 Manuel López-Meseguer verfasserin aut Use of Bacteriophages in Lung Transplantation 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Bacteriophages (phages) are natural predators of bacteria and are becoming increasingly attractive due to the increase of multidrug-resistant organisms (MDROs), especially prevalent among transplant recipients. Antibiotic resistance is the biggest current threat to global health. An increasing number of infections is becoming harder or almost impossible to treat, carrying high morbidity, mortality and financial cost. The therapeutic use of bacteriophages, viruses that infect and kill bacteria, is well suited to be part of the strategies to combat antibiotic resistance. Infections, in particular those due to bacterial pathogens, are common among transplant candidates and recipients. For lung transplant (LTx) patients this is of paramount relevance, since some of the underlying diseases in LTx present recurrent infection and complex colonization (such as cystic fibrosis or bronchiectasis). Individual case reports and small case series suggest the possible efficacy of phage therapy for the treatment in pre- and posttransplant patients. Importantly, there have been no serious safety concerns in the reported cases, so it is reasonable to pursue phage therapy for difficult infections on a compassionate basis. Bacteriophages. Lung transplant. Multi-drug resistant organisms. Diseases of the respiratory system Marta Zapata-Ortega verfasserin aut Cristina Berastegui-Garcia verfasserin aut In Barcelona Respiratory Network Reviews Publicaciones Permanyer, 2022 9(2023), 3 (DE-627)1827079673 23857110 nnns volume:9 year:2023 number:3 https://doi.org/10.23866/BRNRev:2023-M0096 kostenfrei https://doaj.org/article/ec3039ef437e4deab69b8cb849b17568 kostenfrei https://www.brnreviews.com/frame_esp.php?id=237 kostenfrei https://doaj.org/toc/2462-3172 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 9 2023 3 |
allfields_unstemmed |
10.23866/BRNRev:2023-M0096 doi (DE-627)DOAJ101681518 (DE-599)DOAJec3039ef437e4deab69b8cb849b17568 DE-627 ger DE-627 rakwb eng RC705-779 Manuel López-Meseguer verfasserin aut Use of Bacteriophages in Lung Transplantation 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Bacteriophages (phages) are natural predators of bacteria and are becoming increasingly attractive due to the increase of multidrug-resistant organisms (MDROs), especially prevalent among transplant recipients. Antibiotic resistance is the biggest current threat to global health. An increasing number of infections is becoming harder or almost impossible to treat, carrying high morbidity, mortality and financial cost. The therapeutic use of bacteriophages, viruses that infect and kill bacteria, is well suited to be part of the strategies to combat antibiotic resistance. Infections, in particular those due to bacterial pathogens, are common among transplant candidates and recipients. For lung transplant (LTx) patients this is of paramount relevance, since some of the underlying diseases in LTx present recurrent infection and complex colonization (such as cystic fibrosis or bronchiectasis). Individual case reports and small case series suggest the possible efficacy of phage therapy for the treatment in pre- and posttransplant patients. Importantly, there have been no serious safety concerns in the reported cases, so it is reasonable to pursue phage therapy for difficult infections on a compassionate basis. Bacteriophages. Lung transplant. Multi-drug resistant organisms. Diseases of the respiratory system Marta Zapata-Ortega verfasserin aut Cristina Berastegui-Garcia verfasserin aut In Barcelona Respiratory Network Reviews Publicaciones Permanyer, 2022 9(2023), 3 (DE-627)1827079673 23857110 nnns volume:9 year:2023 number:3 https://doi.org/10.23866/BRNRev:2023-M0096 kostenfrei https://doaj.org/article/ec3039ef437e4deab69b8cb849b17568 kostenfrei https://www.brnreviews.com/frame_esp.php?id=237 kostenfrei https://doaj.org/toc/2462-3172 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 9 2023 3 |
allfieldsGer |
10.23866/BRNRev:2023-M0096 doi (DE-627)DOAJ101681518 (DE-599)DOAJec3039ef437e4deab69b8cb849b17568 DE-627 ger DE-627 rakwb eng RC705-779 Manuel López-Meseguer verfasserin aut Use of Bacteriophages in Lung Transplantation 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Bacteriophages (phages) are natural predators of bacteria and are becoming increasingly attractive due to the increase of multidrug-resistant organisms (MDROs), especially prevalent among transplant recipients. Antibiotic resistance is the biggest current threat to global health. An increasing number of infections is becoming harder or almost impossible to treat, carrying high morbidity, mortality and financial cost. The therapeutic use of bacteriophages, viruses that infect and kill bacteria, is well suited to be part of the strategies to combat antibiotic resistance. Infections, in particular those due to bacterial pathogens, are common among transplant candidates and recipients. For lung transplant (LTx) patients this is of paramount relevance, since some of the underlying diseases in LTx present recurrent infection and complex colonization (such as cystic fibrosis or bronchiectasis). Individual case reports and small case series suggest the possible efficacy of phage therapy for the treatment in pre- and posttransplant patients. Importantly, there have been no serious safety concerns in the reported cases, so it is reasonable to pursue phage therapy for difficult infections on a compassionate basis. Bacteriophages. Lung transplant. Multi-drug resistant organisms. Diseases of the respiratory system Marta Zapata-Ortega verfasserin aut Cristina Berastegui-Garcia verfasserin aut In Barcelona Respiratory Network Reviews Publicaciones Permanyer, 2022 9(2023), 3 (DE-627)1827079673 23857110 nnns volume:9 year:2023 number:3 https://doi.org/10.23866/BRNRev:2023-M0096 kostenfrei https://doaj.org/article/ec3039ef437e4deab69b8cb849b17568 kostenfrei https://www.brnreviews.com/frame_esp.php?id=237 kostenfrei https://doaj.org/toc/2462-3172 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 9 2023 3 |
allfieldsSound |
10.23866/BRNRev:2023-M0096 doi (DE-627)DOAJ101681518 (DE-599)DOAJec3039ef437e4deab69b8cb849b17568 DE-627 ger DE-627 rakwb eng RC705-779 Manuel López-Meseguer verfasserin aut Use of Bacteriophages in Lung Transplantation 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Bacteriophages (phages) are natural predators of bacteria and are becoming increasingly attractive due to the increase of multidrug-resistant organisms (MDROs), especially prevalent among transplant recipients. Antibiotic resistance is the biggest current threat to global health. An increasing number of infections is becoming harder or almost impossible to treat, carrying high morbidity, mortality and financial cost. The therapeutic use of bacteriophages, viruses that infect and kill bacteria, is well suited to be part of the strategies to combat antibiotic resistance. Infections, in particular those due to bacterial pathogens, are common among transplant candidates and recipients. For lung transplant (LTx) patients this is of paramount relevance, since some of the underlying diseases in LTx present recurrent infection and complex colonization (such as cystic fibrosis or bronchiectasis). Individual case reports and small case series suggest the possible efficacy of phage therapy for the treatment in pre- and posttransplant patients. Importantly, there have been no serious safety concerns in the reported cases, so it is reasonable to pursue phage therapy for difficult infections on a compassionate basis. Bacteriophages. Lung transplant. Multi-drug resistant organisms. Diseases of the respiratory system Marta Zapata-Ortega verfasserin aut Cristina Berastegui-Garcia verfasserin aut In Barcelona Respiratory Network Reviews Publicaciones Permanyer, 2022 9(2023), 3 (DE-627)1827079673 23857110 nnns volume:9 year:2023 number:3 https://doi.org/10.23866/BRNRev:2023-M0096 kostenfrei https://doaj.org/article/ec3039ef437e4deab69b8cb849b17568 kostenfrei https://www.brnreviews.com/frame_esp.php?id=237 kostenfrei https://doaj.org/toc/2462-3172 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 9 2023 3 |
language |
English |
source |
In Barcelona Respiratory Network Reviews 9(2023), 3 volume:9 year:2023 number:3 |
sourceStr |
In Barcelona Respiratory Network Reviews 9(2023), 3 volume:9 year:2023 number:3 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
Bacteriophages. Lung transplant. Multi-drug resistant organisms. Diseases of the respiratory system |
isfreeaccess_bool |
true |
container_title |
Barcelona Respiratory Network Reviews |
authorswithroles_txt_mv |
Manuel López-Meseguer @@aut@@ Marta Zapata-Ortega @@aut@@ Cristina Berastegui-Garcia @@aut@@ |
publishDateDaySort_date |
2023-01-01T00:00:00Z |
hierarchy_top_id |
1827079673 |
id |
DOAJ101681518 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ101681518</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240414203143.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240414s2023 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.23866/BRNRev:2023-M0096</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ101681518</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJec3039ef437e4deab69b8cb849b17568</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC705-779</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Manuel López-Meseguer</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Use of Bacteriophages in Lung Transplantation</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Bacteriophages (phages) are natural predators of bacteria and are becoming increasingly attractive due to the increase of multidrug-resistant organisms (MDROs), especially prevalent among transplant recipients. Antibiotic resistance is the biggest current threat to global health. An increasing number of infections is becoming harder or almost impossible to treat, carrying high morbidity, mortality and financial cost. The therapeutic use of bacteriophages, viruses that infect and kill bacteria, is well suited to be part of the strategies to combat antibiotic resistance. Infections, in particular those due to bacterial pathogens, are common among transplant candidates and recipients. For lung transplant (LTx) patients this is of paramount relevance, since some of the underlying diseases in LTx present recurrent infection and complex colonization (such as cystic fibrosis or bronchiectasis). Individual case reports and small case series suggest the possible efficacy of phage therapy for the treatment in pre- and posttransplant patients. Importantly, there have been no serious safety concerns in the reported cases, so it is reasonable to pursue phage therapy for difficult infections on a compassionate basis.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Bacteriophages. Lung transplant. Multi-drug resistant organisms.</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the respiratory system</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Marta Zapata-Ortega</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Cristina Berastegui-Garcia</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Barcelona Respiratory Network Reviews</subfield><subfield code="d">Publicaciones Permanyer, 2022</subfield><subfield code="g">9(2023), 3</subfield><subfield code="w">(DE-627)1827079673</subfield><subfield code="x">23857110</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:9</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:3</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.23866/BRNRev:2023-M0096</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/ec3039ef437e4deab69b8cb849b17568</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.brnreviews.com/frame_esp.php?id=237</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2462-3172</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">9</subfield><subfield code="j">2023</subfield><subfield code="e">3</subfield></datafield></record></collection>
|
callnumber-first |
R - Medicine |
author |
Manuel López-Meseguer |
spellingShingle |
Manuel López-Meseguer misc RC705-779 misc Bacteriophages. Lung transplant. Multi-drug resistant organisms. misc Diseases of the respiratory system Use of Bacteriophages in Lung Transplantation |
authorStr |
Manuel López-Meseguer |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)1827079673 |
format |
electronic Article |
delete_txt_mv |
keep |
author_role |
aut aut aut |
collection |
DOAJ |
remote_str |
true |
callnumber-label |
RC705-779 |
illustrated |
Not Illustrated |
issn |
23857110 |
topic_title |
RC705-779 Use of Bacteriophages in Lung Transplantation Bacteriophages. Lung transplant. Multi-drug resistant organisms |
topic |
misc RC705-779 misc Bacteriophages. Lung transplant. Multi-drug resistant organisms. misc Diseases of the respiratory system |
topic_unstemmed |
misc RC705-779 misc Bacteriophages. Lung transplant. Multi-drug resistant organisms. misc Diseases of the respiratory system |
topic_browse |
misc RC705-779 misc Bacteriophages. Lung transplant. Multi-drug resistant organisms. misc Diseases of the respiratory system |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
Barcelona Respiratory Network Reviews |
hierarchy_parent_id |
1827079673 |
hierarchy_top_title |
Barcelona Respiratory Network Reviews |
isfreeaccess_txt |
true |
familylinks_str_mv |
(DE-627)1827079673 |
title |
Use of Bacteriophages in Lung Transplantation |
ctrlnum |
(DE-627)DOAJ101681518 (DE-599)DOAJec3039ef437e4deab69b8cb849b17568 |
title_full |
Use of Bacteriophages in Lung Transplantation |
author_sort |
Manuel López-Meseguer |
journal |
Barcelona Respiratory Network Reviews |
journalStr |
Barcelona Respiratory Network Reviews |
callnumber-first-code |
R |
lang_code |
eng |
isOA_bool |
true |
recordtype |
marc |
publishDateSort |
2023 |
contenttype_str_mv |
txt |
author_browse |
Manuel López-Meseguer Marta Zapata-Ortega Cristina Berastegui-Garcia |
container_volume |
9 |
class |
RC705-779 |
format_se |
Elektronische Aufsätze |
author-letter |
Manuel López-Meseguer |
doi_str_mv |
10.23866/BRNRev:2023-M0096 |
author2-role |
verfasserin |
title_sort |
use of bacteriophages in lung transplantation |
callnumber |
RC705-779 |
title_auth |
Use of Bacteriophages in Lung Transplantation |
abstract |
Bacteriophages (phages) are natural predators of bacteria and are becoming increasingly attractive due to the increase of multidrug-resistant organisms (MDROs), especially prevalent among transplant recipients. Antibiotic resistance is the biggest current threat to global health. An increasing number of infections is becoming harder or almost impossible to treat, carrying high morbidity, mortality and financial cost. The therapeutic use of bacteriophages, viruses that infect and kill bacteria, is well suited to be part of the strategies to combat antibiotic resistance. Infections, in particular those due to bacterial pathogens, are common among transplant candidates and recipients. For lung transplant (LTx) patients this is of paramount relevance, since some of the underlying diseases in LTx present recurrent infection and complex colonization (such as cystic fibrosis or bronchiectasis). Individual case reports and small case series suggest the possible efficacy of phage therapy for the treatment in pre- and posttransplant patients. Importantly, there have been no serious safety concerns in the reported cases, so it is reasonable to pursue phage therapy for difficult infections on a compassionate basis. |
abstractGer |
Bacteriophages (phages) are natural predators of bacteria and are becoming increasingly attractive due to the increase of multidrug-resistant organisms (MDROs), especially prevalent among transplant recipients. Antibiotic resistance is the biggest current threat to global health. An increasing number of infections is becoming harder or almost impossible to treat, carrying high morbidity, mortality and financial cost. The therapeutic use of bacteriophages, viruses that infect and kill bacteria, is well suited to be part of the strategies to combat antibiotic resistance. Infections, in particular those due to bacterial pathogens, are common among transplant candidates and recipients. For lung transplant (LTx) patients this is of paramount relevance, since some of the underlying diseases in LTx present recurrent infection and complex colonization (such as cystic fibrosis or bronchiectasis). Individual case reports and small case series suggest the possible efficacy of phage therapy for the treatment in pre- and posttransplant patients. Importantly, there have been no serious safety concerns in the reported cases, so it is reasonable to pursue phage therapy for difficult infections on a compassionate basis. |
abstract_unstemmed |
Bacteriophages (phages) are natural predators of bacteria and are becoming increasingly attractive due to the increase of multidrug-resistant organisms (MDROs), especially prevalent among transplant recipients. Antibiotic resistance is the biggest current threat to global health. An increasing number of infections is becoming harder or almost impossible to treat, carrying high morbidity, mortality and financial cost. The therapeutic use of bacteriophages, viruses that infect and kill bacteria, is well suited to be part of the strategies to combat antibiotic resistance. Infections, in particular those due to bacterial pathogens, are common among transplant candidates and recipients. For lung transplant (LTx) patients this is of paramount relevance, since some of the underlying diseases in LTx present recurrent infection and complex colonization (such as cystic fibrosis or bronchiectasis). Individual case reports and small case series suggest the possible efficacy of phage therapy for the treatment in pre- and posttransplant patients. Importantly, there have been no serious safety concerns in the reported cases, so it is reasonable to pursue phage therapy for difficult infections on a compassionate basis. |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
container_issue |
3 |
title_short |
Use of Bacteriophages in Lung Transplantation |
url |
https://doi.org/10.23866/BRNRev:2023-M0096 https://doaj.org/article/ec3039ef437e4deab69b8cb849b17568 https://www.brnreviews.com/frame_esp.php?id=237 https://doaj.org/toc/2462-3172 |
remote_bool |
true |
author2 |
Marta Zapata-Ortega Cristina Berastegui-Garcia |
author2Str |
Marta Zapata-Ortega Cristina Berastegui-Garcia |
ppnlink |
1827079673 |
callnumber-subject |
RC - Internal Medicine |
mediatype_str_mv |
c |
isOA_txt |
true |
hochschulschrift_bool |
false |
doi_str |
10.23866/BRNRev:2023-M0096 |
callnumber-a |
RC705-779 |
up_date |
2024-07-03T21:57:42.631Z |
_version_ |
1803596713327329280 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ101681518</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240414203143.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240414s2023 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.23866/BRNRev:2023-M0096</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ101681518</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJec3039ef437e4deab69b8cb849b17568</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC705-779</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Manuel López-Meseguer</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Use of Bacteriophages in Lung Transplantation</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Bacteriophages (phages) are natural predators of bacteria and are becoming increasingly attractive due to the increase of multidrug-resistant organisms (MDROs), especially prevalent among transplant recipients. Antibiotic resistance is the biggest current threat to global health. An increasing number of infections is becoming harder or almost impossible to treat, carrying high morbidity, mortality and financial cost. The therapeutic use of bacteriophages, viruses that infect and kill bacteria, is well suited to be part of the strategies to combat antibiotic resistance. Infections, in particular those due to bacterial pathogens, are common among transplant candidates and recipients. For lung transplant (LTx) patients this is of paramount relevance, since some of the underlying diseases in LTx present recurrent infection and complex colonization (such as cystic fibrosis or bronchiectasis). Individual case reports and small case series suggest the possible efficacy of phage therapy for the treatment in pre- and posttransplant patients. Importantly, there have been no serious safety concerns in the reported cases, so it is reasonable to pursue phage therapy for difficult infections on a compassionate basis.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Bacteriophages. Lung transplant. Multi-drug resistant organisms.</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the respiratory system</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Marta Zapata-Ortega</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Cristina Berastegui-Garcia</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Barcelona Respiratory Network Reviews</subfield><subfield code="d">Publicaciones Permanyer, 2022</subfield><subfield code="g">9(2023), 3</subfield><subfield code="w">(DE-627)1827079673</subfield><subfield code="x">23857110</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:9</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:3</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.23866/BRNRev:2023-M0096</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/ec3039ef437e4deab69b8cb849b17568</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.brnreviews.com/frame_esp.php?id=237</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2462-3172</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">9</subfield><subfield code="j">2023</subfield><subfield code="e">3</subfield></datafield></record></collection>
|
score |
7.4006443 |